New pill aims to control hepatitis b in early trial

NCT ID NCT05960240

First seen Apr 15, 2026 · Last updated May 15, 2026 · Updated 9 times

Summary

This early-phase study tested a new oral drug called AB-101 in 128 people, including healthy volunteers and patients with chronic hepatitis B. The main goal was to check safety and how the body processes the drug. It is not a cure, but a step toward better disease control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • ASST Papa Giovanni XXIII -Osepedale

    Bergamo, Italy

  • Clinial Republican Hospital "Timofei Mosneaga"

    Chisinau, Moldova

  • Clinical Republican Hospital "Timofei Mosneaga", ARENSIA E. M.

    Bucharest, Romania

  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • Municipal Non-Profit Enterprise Kyiv City Clinical Hospital No12 Executive Body of Kyiv City Council

    Kyiv, Ukraine

  • National University Hospital

    Singapore, Singapore

  • New Zealand Clinical Research Auckland

    Grafton, Auckland, New Zealand

  • Prince of Wales Hospital

    Hong Kong, Hong Kong, Hong Kong

  • Queen Mary Hospital - PPDS

    Hong Kong, Hong Kong, Hong Kong

  • Singapore General Hospital

    Singapore, Singapore

Conditions

Explore the condition pages connected to this study.